Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: A pilot study

Cancer

Volumn 86, Issue 2, 1999, Pages 325-330

  Menei, Philippe ^a   Venier, Marie Claire ^a   Gamelin, Erik ^b   Saint Andŕe, Jean Paul ^a   Hayek, Ghassan ^a   Jadaud, Eric ^b   Fournier, Dominique ^a   Mercier, Philippe ^a   Gilles, Guy ^a   Benoit, Jean Pierre ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b CENTRE PAUL PAPIN   (France)

Author keywords

5 fluorouracil; Brain tumor; Chemotherapy; Drug delivery; Glioblastoma; Microsphere; Radiosensitization

Indexed keywords

FLUOROURACIL; MICROSPHERE; POLYGLACTIN; RESOMER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIODEGRADATION; BRAIN DISEASE; BRAIN EDEMA; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CEREBELLUM DISEASE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG IMPLANT; FEMALE; GLIOBLASTOMA; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; SUSTAINED DRUG RELEASE;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BIODEGRADATION, ENVIRONMENTAL; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; FLUOROURACIL; GLIOBLASTOMA; HUMANS; MALE; MICROSPHERES; MIDDLE AGED; PILOT PROJECTS; RADIATION-SENSITIZING AGENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033566005     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990715)86:2<325::AID-CNCR17>3.0.CO;2-S     Document Type: Article

References (35)

1. Kornblith PL, Walker M. Chemotherapy for malignant gliomas. J Neurosurg 1988;68:1-17.
2. Burger PC, Dubois PJ, Schold SC, Smith KR, Odom GL, Crafts DC, et al. Computerized tomographic and pathologic studies of the untreated, quiescent and recurrent glioblastoma multiforme. J Neurosurg 1983;58:159-9.
3. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30:907-11.
4. Brem H, Mahaley MS, Vick NA, Black KL, Schold SC, Burger PC, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991;74:441-6.
5. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995; 345:1008-12.
6. Kubo O, Himuro H, Inoue N, Tajika Y, Tajika T, Tohyama T, et al. Treatment of malignant brain tumors with slowly releasing anticancer drug-polymer composites. No Shinkei Geka 1986;14:1189-95.
7. Oda Y, Uchida Y, Murata T, Mori K, Tokuriki Y, Handa H, et al. Treatment of brain tumors with anticancer pellet. Experimental and clinical study. No Shinkei Geka 1982;10:375-81.
8. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997;41:44-8.
9. Menei P, Croué A, Daniel V, Pouplard-Barthelaix A, Benoit JP. Fate and biocompatibility of three types of microspheres implanted into the brain. J Biomed Mater Res 1994;28:1079-85.
10. Menei P, Benoit JP, Boisdron-Celle M, Fournier D, Mercier P, Guy G. Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres. Neurosurgery 1994;34:1058-64.
11. Menei P, Daniel V, Montero-Menei C, Brouillard M, Pouplard-Barthelaix A, Benoit JP. Biodegradation and brain tissue reaction to poly(D-L lactide-co-glycolide) microspheres. Biomaterials 1993;14:470-8.
12. Lawrence TS, Maybaum J. Fluoropyrimidines as radiation sensitizers. Semin Radiat Oncol 1993;3:20-8.
13. Boisdron-Celle M, Menei P, Benoit JP. Preparation and characterization of 5-fluorouracil-loaded microparticles as biodegradable anticancer drug carriers. J Pharm Pharmacol 1995;47:108-14.
14. Menei P, Boisdron-Celle M, Croué A, Guy G, Benoit JP. Effect of stereotactic implantation of biodegradable 5-Fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery 1996;39:117-24.
15. Heihues P, Burger PC, Scheithauer BW. World Health Organization histological typing of tumors of the central nervous system. New York: Springer-Verlag, 1993.
16. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, et al. Relationship between 5-fluorouracil dose-intensity and therapeutic response in patients with advanced colorectal cancer receiving 5-FU containing infusional therapy. Cancer 1996;77:441-51.
17. Cascino TL, Veeder MH, Buckner JC, O'Fallon JR, Wiesenfeld M, Levitt R, et al. Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor. J Neurooncol 1996;30:243-6.
18. 14C and its metabolites in a murine glioma. J Natl Cancer Inst 1972;49:1577-84.
19. Levin VA, Edwards MS, Wara WM, Allen J, Ortega J, Vestnys P. 5-fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Children Cancer Group. Neurosurgery 1984;14:679-81.
20. Neuwelt EA, Barnett PA, Frenkel EP. Chemotherapeutic agent permeability to normal brain and delivery to avian sarcoma virus-induced brain tumors in the rodent: observations on problems of drug delivery. Neurosurgery 1984;14: 154-60.
21. Shapiro WR. Studies on the chemotherapy of experimental brain tumors: evaluation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, vincristine and 5-fluorouracil. J Natl Cancer Inst 1971;46:359-68.
22. Shapiro WR, Green SB, Burger PC, Selker RG, VanGilder JC, Robertson JT, et al. A randomized comparison of intraarterial versus intravenous BCNU with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992;76:772-81.
23. Kroin JS, Ali A, York M, Penn RD. The distribution of medication along spinal canal after chronic intrathecal administration. Neurosurgery 1993;33:226-30.
24. Chen TC, Hinton DR, Leichman L, Atkinson RD, Apuzzo MLJ, Couldwell WT. Multifocal inflammatory leukoencephalopathy associated with levamisole and 5-fluorouracil: case report. Neurosurgery 1994;35:1138-43.
25. Luppi G, Zoboli A, Barbieri F, Crisi G, Piccinini L, Silingardi V. Multifocal leukoencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer. A report of two cases and review of the literature. Ann Oncol 1996;7:412-5.
26. Moore DH, Fowler WC, Crumpler LS. 5-fluorouracil neurotoxicity. Gynecol Oncol 1990;36:152-4.
27. Ringkjob R. Treatment of intracranial gliomas and metastatic carcinomas by local application of cytostatic agents. Acta Neurol Scand 1968;44:318-22.
28. Young DF, Posner JB, Chu F. Rapid-course radiation therapy of cerebral metastases: results and complications. Cancer 1974;34:1069-76.
29. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 1993;78:767-75.
30. Hirakawa K, Suzuki K, Ueda S, Nakagawa Y, Yoshino E, Ibayashi N, et al. Multivariate analysis of factors affecting postoperative survival in malignant astrocytoma. J Neurooncol 1984;2:331-40.
31. Kou JH, Emmett C, Shen P, Aswani S, Iwamoto T, Vaghefi F, et al. Bioerosion and biocompatibility of poly(d,l-lactic-co-glycolic acid) implants in brain. J Control Release 1997;43: 123-30.
32. Torres AI, Boisdron-Celle M, Benoit JP. Formulation of BCNU-loaded microspheres: influence of drug stability and solubility on the design of the microencapsulation procedure. J Microencapsul 1996;13:41-51.
33. Chen W, He J, Olson JF, Lu OR. Carboplatin-loaded PLGA microspheres for intracerebral implantation: in vivo characterization. Drug Delivery 1997;4:301-11.
34. Beer SJ, Hilfinger JM, Davidson BL. Extended release of adenovirus from polymer microspheres: potential use in gene therapy for brain tumors. Adv Drug Deliver Rev 1997; 27:59-66.
35. Menei P, Venier-Julienne MC, Benoit JP. Drug delivery into the brain using implantable polymeric systems. STP Pharma Sciences 1997;7:53-61.